Biostax Corp (BTAX)

[H1C]

Herold, Dr. Jill Smith conducted Phase 2 trials for LDN for Crohn's. She talks about them in the video I linked to earlier:

The whole thing's worth a watch, because she explains LDN's mechanisms of action so clearly, and gives a nice overview of the trials she's done.

I believe that the FDA relied on Dr. Smith's earlier work in giving IMUN the go-ahead in January 2018 to apply for Phase 3 trials.

Dr. Smith is one of the major patent owners that IMUN bought IP from. She likely was paid partly in equity in IMUN.

I too am curious how they'll fund the Phase 3 trials. I hope you and dwarren are right, and that it'll be from a combination of revenue from Africa, and a US government grant. LDN is exactly the kind of drug that CMS desperately needs to curb Medicare and Medicaid costs.

The 10-K is due before the end of the quarter, so hopefully we will get more details this week.